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I. Introduction: Cellular Basis of Carcinogenesis
Cancer is a disease of uncontrolled growth and proliferation whereby cells have
escaped the body’s normal growth control mechanisms and have gained the ability to
divide indefinitely. It is a multistep process that requires the accumulation of many
genetic changes over time (Figure 1). These genetic alterations involve activation of
proto-oncogenes to oncogenes, deregulation of tumour suppressor genes and DNA
repair genes and ‘immortalisation’ which will be discussed in further detail in Sections
I-IV of this chapter.

Figure 1: Overview of the road to cancer. Cells may acquire mutations in genes that control
proliferation, such as proto-oncogenes and/or tumor suppressor genes. Each new mutation
may provide a selective advantage for this cell, leading to ‘clonal expansion’. Cellular
properties changed in this process include cell cycle deregulation, apoptosis prevention and
cell adhesion properties (CAMs – Cellular adhesion molecules). Image from Alison, MR,
Cancer. Encyclopedia of Life Sciences, 2001 (DOI: 10.1038/npg.els.0001471). Reproduced
with permission from John Wiley & Sons.

1. Cell cycle regulation and the importance of apoptosis
In normal cells, proliferation and progression through the cell cycle is strictly
regulated by groups of proteins that interact with each other in a specific sequence of
events (Figure 2). Checkpoints ascertain that individual stages of the cell cycle are
completed correctly and ensure that incompletely replicated DNA is not passed onto
daughter cells. Core to this control system are cyclin-dependent kinases (CDKs).
CDKs are ‘master protein kinases’ that drive progression through the different phases
of the cell cycle by phosphorylating and activating other downstream kinases. CDK
activity is dependent on the presence of activating subunits called cyclins which are
synthesised and degraded in a cell cycle-dependent manner. Cyclin-CDK complexes
are further tightly regulated by CDK inhibitors.

3

Figure 2: Cyclins and cyclin-dependent kinases (CDKs) regulate the cell cycle. CDK’s
and their regulatory subunits, cyclins (A, B, D & E) tightly control transition through the cell
cycle. The brackets indicate the periods in which the cyclin-CDK complexes are active and
orchestrate all events necessary in this period. The restriction point (R point) is a point in G1
at which the cell becomes ‘committed’ to the cell cycle and after which extracellular
st
proliferation signals are no longer required. ©2007 from The Biology of Cancer, 1 ed. by RA
Weinberg. Reproduced with permission of Garland Science/Taylor & Francis LLC.

The re-entry of cells into the cell cycle is decided at the restriction point (R point).
This decision is influenced by extracellular mitogenic signals which are transmitted
via signalling pathways to key regulatory proteins such as transcription factors (e.g.
E2F) in the nucleus (refer to Figure 3, Section II). These regulatory proteins ultimately
activate the S-phase CDKs, which trigger the start of DNA synthesis.
In normal cells, activation of another transcription factor, p53, often referred to as the
‘guardian of the genome’, can impose cell cycle arrest and induce apoptosis
(programmed cell death) through its ability to:
 Induce the expression of cell cycle inhibitors to prevent proliferation of a cell until
any damage has been repaired or
 Initiate apoptosis, if the genomic damage is too great and cannot be repaired.
In >50% of all human tumours the p53 pathway is aberrant. Inactivation of the p53
protein renders it unable to signal and activate the cell’s apoptotic machinery
resulting in increased survival of cancer cells.
2. Cell immortalisation and tumourigenesis
Immortalisation is defined as the acquisition of an infinite life span. Normal
mammalian somatic cells proliferate a limited number of times before undergoing
senescence. Senescent cells may remain metabolically active even though they have
permanently ceased proliferation. Immortalisation is an essential step in the
malignant transformation of normal cells and can be attributed, in part, to the
presence of telomerase, the enzyme responsible for maintaining telomeres at the
ends of chromosomes. By extending telomeric DNA, telomerase is able to counter
the progressive telomere shortening that would otherwise lead to cell death. Unlike
normal cells that lack detectable levels of telomerase activity, approximately 90% of
human tumours consist of cells that contain an active telomerase enzyme.
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II. Cell Signalling in Carcinogenesis
1. Growth factors and their receptors
Growth factors (GFs) play an important physiological role in the normal process of
growth control aimed at maintaining tissue homeostasis. They transmit growth
signals from one cell to another. These signals are sensed on the cell surface by
specific growth factor receptors (GFRs). GFRs transfer the growth signal via
signalling pathways to activate target molecules that promote proliferation (Figure 3).

Figure 3: The MAP kinase pathway as an example of a growth signalling pathway.
The mitogen (or growth factor) binds to its receptor, a receptor tyrosine kinase. Tyrosine
phosphorylation of the receptor leads to activation of several docking proteins, and eventually
to the activation Ras, bound to the inside of the cell membrane. Active Ras in turn activates
the MAP kinase signalling cascade, beginning with Raf (not shown here). The final MAP
kinase in this sequence activates several target proteins, for example a transcription factor
that activates expression of the Myc gene. Myc itself is a transcription factor that activates the
th
expression of cell cycle regulatory genes. ©2002 from Molecular Biology of the Cell, 4 Ed. by
Alberts et al. Reproduced with permission of Garland Science/Taylor & Francis LLC.

Steps that characterise normal cell proliferation include:
 The binding of a GF to its specific receptor on the cell membrane
 Transient and limited activation of the GFR, which, activates several signaltransducing proteins (e.g. Ras) on the inner leaflet of the plasma membrane
 Transmission of the signal by signal transduction molecules, either to cytosolic
targets or to the nucleus where they activate transcription of specific genes
 Entry of the cell into the cell cycle, ultimately resulting in cell division
This pathway is often derailed in cancer and allows wayward cells to generate their
own internal signals that stimulate proliferation and become independent of their

5
environments. Cancer cells are able to induce their own growth stimulatory signals
when mutations in the GFR gene occur, which facilitates activation in the absence of
GFs or when overproduction of GFs results in an autocrine signalling loop.
2. Other elements of cell signalling
An alternative strategy by which cancer cells can become GF independent involves
constitutive activation of internal signalling components. For example, the Ras protein
in normal cells is switched off and does not signal unless a GFR becomes activated,
which through a series of intermediaries, is able to activate the Ras protein,
converting it from its quiescent state to an active, signal-emitting state. Thereafter,
the Ras protein is able to release further downstream signals that are capable of
inducing proliferation. In cancer cells, this signalling pathway is deregulated because
structurally altered Ras proteins are able to continuously send growth stimulatory
signals into the interior of the cell in the absence of GFs.

III. Genes Frequently Mutated in Cancer
The genes that have been implicated in carcinogenesis are divided into two broad
categories oncogenes (‘cell accelerators’) and tumour suppressor genes (‘cell
brakes’) but also include DNA repair genes (See section IV.3 for further detail).
1. Cellular oncogenes
Genes that promote autonomous cell growth in cancer cells are called oncogenes,
and their normal cellular counterparts are called proto-oncogenes. Proto-oncogenes
are physiologic regulators of cell proliferation and differentiation while oncogenes are
characterised by the ability to promote cell growth in the absence of normal mitogenic
signals. Their products, oncoproteins, resemble the normal products of protooncogenes with the exception that oncoproteins are devoid of important regulatory
elements. Their production in the transformed cells becomes constitutive, that is, not
dependent on growth factors or other external signals. Proto-oncogenes can be
converted to oncogenes by several mechanisms including point mutation and gene
amplification resulting in:
 Overproduction of growth factors
 Flooding of the cell with replication signals
 Uncontrolled stimulation in the intermediary pathways
 Cell growth by elevated levels of transcription factors
The RAS oncogene is the most frequently mutated oncogene in human cancer. It
encodes a GTP-binding protein Ras that functions as an on-off ‘switch’ for a number
of key signalling pathways controlling cellular proliferation. In a normal cell, Ras is
transiently activated and recruits Raf, to activate the MAP-kinase pathway to transmit
growth-promoting signals to the nucleus. The mutant Ras protein is permanently
activated, leading to continuous stimulation of cells without any external trigger. Other
oncogenes frequently mutated in cancer are listed in Table 1.
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Table 1. Selected Oncogenes and Associated Cancers
Protooncogene

Mode of
Activation

Associated Cancer

PDGF (β chain)

SIS

Overexpression

Astrocytoma, osteosarcoma

Fibroblast growth factors

HST-1

Overexpression

Stomach cancer

INT-2

Amplification

Bladder & breast cancer

Category / Protein Function
Growth Factors

Melanoma
Transforming growth factor α

TGFα

Overexpression

Astrocytomas
Hepatocellular carcinomas

Growth Factor Receptors
EGF-receptor family

ERB-B1

Overexpression

SCC of the lung, gliomas

ERB-B2

Amplification

Breast and ovarian cancers

PDGF receptor

PDGF-R

Overexpression

Gliomas

Receptor for stem cell
(steel) factor

KIT

Point mutation

Gastrointestinal stromal tumours

K-RAS

Point mutation

Colon, lung, pancreatic tumours

H-RAS

Point mutation

Bladder & kidney tumours

N-RAS

Point mutation

Melanoma, leukaemia, lymphoma

Non-receptor tyrosine kinase

ABL

Translocation

CML, ALL

RAS signal transduction

BRAF

Point mutation

Melanomas

WNT signal transduction

β-catenin

Point mutation/

Hepatoblastomas & HCC

Proteins Involved in Signal
Transduction
GTP-binding

Overexpression
Nuclear Regulatory Proteins
Transcriptional activators

C-MYC

Translocation

N-MYC

Amplification

Burkitt lymphoma
Neuroblastoma, small cell
carcinoma of lung

L-MYC

Amplification

SCC of the lung

CYCLIN D

Translocation

Mantle cell lymphoma

Amplification

Breast & oesophageal cancers

Cell-Cycle Regulators
Cyclins

CYCLIN E

Overexpression
Breast cancer
Amplification or
Glioblastoma, melanoma,
Cyclin-dependent kinase
CDK4
Point mutation
sarcoma
(adapted from Table 7-6, Kumar et al, Robbins & Cotran’s Pathological Basis of Disease, 8th ed.
Elsevier 2010)

2. Tumour suppressor genes
Tumour suppressor genes (Table 2) encode proteins that are:
 Receptors for secreted hormones that function to inhibit cell proliferation
 Negative regulators of cell cycle entry or progression
 Negative regulators of growth signalling pathways (e.g. APC or PTEN)
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Checkpoint-control proteins that arrest the cell cycle if DNA is damaged or
chromosomes are abnormal
 Proteins that promote apoptosis
 DNA repair enzymes
The transformation of a normal cell to a cancer cell is accompanied by the loss of
function of one or more tumour suppressor genes and both gene copies must be
defective in order to promote tumour development (see section VI.2).
Table 2. Examples of Tumour Suppressor Genes
Gene

Protein function

Inherited Disease

Spontaneous Tumours

APC

Negative regulator of the
Wnt signalling pathway
Components of DNA repair
systems

Adenomatous
polyposis coli (APC)
Familial breast and
ovarian cancer

Most colon cancers

CDH1

E-cadherin, a cell adhesion
molecule

Hereditary diffuse
gastric cancer

Many epithelial cancers

CDKN2A

INK4a, inhibitor of cyclindependent kinase Cdk4

Some familial
melanomas

Some esophageal and
pancreatic cancers

MEN1

Transcription factor and
protein kinase

Multiple endocrine
neoplasia

Many metastatic cancers

NF1

Neurofibromin, RasGTPase activation

Neurofibromatosis
type 1

Some tumors of neural crest
origin

PTEN

Negative regulator of PI3K
growth signalling pathway

Cowden disease

30%-50% of spontaneous
cancers

RB

Repression of transcription
factor E2F

Retinoblastoma,
osteosarcoma

Retinoblastoma, sarcomas,
several carcinomas

SMAD4

Signal transducer in TGF-
signalling

Juvenile polyposis

Colon and pancreatic cancers

TP53

Transcription factor;
'guardian of the genome'

Li-Fraumeni
syndrome

Most frequently mutated in
human cancers

TSC1,
TSC2
VHL

Inhibitor of mTOR

Tuberous sclerosis

Rare

Ubiquitin ligase

von Hippel-Lindau
disease

Many renal cell carcinomas

WT1

Transcription factor

Wilms tumor

Some leukaemias

BRCA1,
BRCA2

Spontaneous breast cancers

st

(Adapted from Table 7.1; Weinberg RA, Biology of Cancer, 1 ed, Garland Science 2007)

The retinoblastoma (Rb) protein is a tumor suppressor gene that controls the cell
cycle transition from G1 to S Phase. Rb protein binds regulatory transcription factor
E2F which is required for the synthesis of DNA replication enzymes. When Rb is
bound to E2F, transcription/replication is blocked. The presence of growth factors
(via the Ras pathway) activates cyclin-dependent kinase 4/6 (Figure 2) Active
CDK4/6- phosphorylates and inhibits Rb, taking the brakes off E2F, and transition to
S phase occurs. Disruption/deletion of the Rb gene therefore leads to uncontrolled
cell proliferation.
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IV. Causes of Cancer
1. Mutations and cancer
Cancer development is based on the accumulation of somatic mutations over
lifetime. Germ line mutations are typically not involved, but in very rare cases of
inherited cancer predisposition, they are contributing to disease progression.
Typically the basal mutation rate is low in humans, but it may be enhanced through
one of the three following groups of environmental carcinogens: chemical
mutagens, radiation and tumour viruses. Exposure to mutagens or radiation
greatly increases the mutation rate and thus the probability of developing cancer.
 Chemical mutagens comprise a quite disparate group of chemicals that modify
DNA through a range of mechanisms, such as alkylation or deamination of DNA
bases, or through intercalation between base pairs and formation of DNA adducts
(e.g. aromatic hydrocarbons). Oxidative damage may also affect DNA integrity.
 X-rays and radioactive radiation tend to induce DNA double-strand breaks,
whereas UV radiation results in the formation of pyrimidine dimers, by crosslinking of adjacent pyrimidine bases.
Table 3 Human Tumour Viruses
Virus (Group)

Associated Human Cancer

DNA VIRUSES
Papilloma virus family
Human papilloma virus (HPV)

Genital tumours, squamous

(various subtypes)

cell carcinoma

Herpes virus family
Human herpes virus 8 (HHV8)

Kaposi sarcoma

Epstein-Barr virus (EBV)

Burkitt's lymphoma, Hodgkin's disease,
Nasopharyngeal carcinoma

Hepadnavirus family
Hepatitis B virus

Hepatocellular carcinoma

RNA VIRUSES
Retrovirus family
Human T-cell leukaemia virus

Adult T-cell leukaemia

Human immunodeficiency virus

AIDS-related malignancies

Flavivirus family
Hepatitis C virus

Hepatocellular carcinoma
th

(Adapted from Table 43-1, Jawetz, Melnick & Adelberg’s Medical Microbiology, 24
ed. McGraw-Hill 2007)

2. Viral causes of cancer
Certain viruses, derived from quite different taxonomic groups (Table 3), are able to
induce cancer development. We distinguish the highly oncogenic viruses, which
contain viral oncogenes in their genomes that are in most cases derived from
cellular proto-oncogenes, whereas slowly transforming viruses do not contain
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such genes. They tend to use one of the following mechanisms to stimulate
proliferation of their host cells:
 Insertion of a strong promoter in the vicinity of a host cell proto-oncogene
 Expression of proteins that neutralise host cell tumour suppressor proteins
 Expression of proteins that prevent or delay apoptosis
Characteristics of viral carcinogenesis include:
 Tumour viruses often establish persistent infections in the human host
 Host factors are important determinants of virus-induced carcinogenesis
 Viruses are rarely complete carcinogens; they require additional factors to fully
activate carcinogenesis.
3. The importance of DNA repair systems
Sophisticated DNA repair systems have evolved in order to maintain the human
genome, by fixing damage that may have occurred to the DNA. Principal DNA repair
mechanisms include: mismatch repair, base and nucleotide excision repair,
repair of depurinated sites and repair of double-strand breaks.
The importance of these repair systems for protection against accelerated
mutagenesis and the development of cancer is impressively demonstrated through
rare inherited cancer predisposition syndromes based on mutations in DNA repair
enzyme systems (Table 4).
Table 4 Inherited Diseases Caused by DNA Repair Defects
Clinical
Manifestation

Disease

Protein Affected

Affected Function

Bloom syndrome

13 different proteins

Recombination repair?

Breast cancer
susceptibility

BRCA1, BRCA2;
proteins of DNA
repair complexes

Homology-directed DNA
repair

Cockayne
syndrome

Nucleotide excision
repair protein

Transcription-coupled
nucleotide excision repair

Poor growth, early
senility, neurological
degeneration

Fanconi anemia

8 different proteins

Repair of DNA cross-links?

Hereditary
nonpolyposis colon
cancer (HNPCC)
Nijmegen breakage
syndrome

Proteins of mismatch
repair

Post-replication mismatch
repair

Anaemia, leukaemia,
chromosome
breakage
Cancer susceptibility

Activator of nuclear
protein kinases

Signalling for DNA doublestrand break repair

Growth retardation,
immunodeficiency,
cancers

Werner syndrome

DNA helicase and
exonuclease

Unknown

Premature aging,
short telomeres

Xeroderma
pigmentosum

Nucleotide excision
repair proteins

Genome-wide nucleotide
excision repair

Cutaneous
photosensitivity

Immunodeficiency,
cancer susceptibility,
chromosome breaks
Breast and ovarian
cancer

rd

(Adapted from Table 9.1, Meisenberg & Simmons, Principles of Medical Biochemistry, 3 ed.
Mosby/Elsevier 2012)
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V. Multistep Carcinogenesis
Carcinogenesis can be considered as a complex micro-evolutionary process, which
requires the accumulation of a range of (somatic) genetic mutations (Figure 1). Under
selection pressure and through these mutations, cells acquire new characteristics,
which provide them with an advantage in growth behaviour and other cellular
properties, such as enhanced survival and invasiveness. This process is in most
cases drawn out over many years and requires a series of individual steps.
1. The main stages of carcinogenesis – an overview
There are three major qualitative changes, which cells have to undergo in order to
successfully proceed through the complete process of carcinogenesis, malignant
transformation, invasion of neighbouring tissues and metastasis. Each one of
these major stages comprises a series of genetic alteration of cells affecting specific
genes that are involved in regulating cell properties relevant for the individual stage,
i.e. growth behaviour (for malignant transformation), invasive properties and
metastatic potential.
2. Early steps characterised in colon cancer
The best characterised example supporting the theory of multi-step carcinogenesis is
colorectal cancer. This is largely due to the relative accessibility of colon cancer
samples and due to the availability of the distinct histo-morphological description of
early stages of cancer development. Genetic characterisation of a large number of
early, intermediate and late adenomas and frank carcinomas led to the establishment
of a ‘preferred’ sequence of genetic alterations during the adenoma-adenocarcinoma
pathway of colorectal cancer (Figure 4). These include the activation of the K-ras
oncogene from its cellular proto-oncogene (pink letters) and the loss for three tumour
suppressor genes (blue letters), where loss of APC (adenomatous polyposis coli) is
an early event, whereas loss of p53 is normally a late event.

Figure 4: Genetic events in early colon carcinoma progression. Approximate correlation
of early genetic events in the development of colon carcinoma (the adenoma-adenocarcinoma pathway) with histopathological features. Note that clinical staging typically refers
to the later observations and cannot be correlated with the genetic events. Genetic events are
indicated by vertical arrows and colour-coded as follows: Blue: loss of tumour suppressor
gene (TSG) function, red: activation of oncogenes, green: epigenetic events. The sequence of
genetic events is not necessarily obligatory, but loss of APC is typically the first event and
st
loss of p53 typically the last one. ©2007 from The Biology of Cancer, 1 ed. by Weinberg.
Reproduced with permission of Garland Science/Taylor & Francis LLC.
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3. Cellular principles of invasion and metastasis
The spread of cancer cells to distant sites in the body via the blood
stream/lymphatics is known as metastasis and is the most lethal form of the disease
(Figure 5). Metastatic cells are less adhesive than normal cells and are able to
degrade and penetrate tissue barriers such as the extracellular matrix (ECM) of
surrounding connective tissue and the basement membrane of blood vessels. After
gaining access to the systemic circulation they can invade normal tissue at various
sites in the body forming secondary colonies. The invasion - metastasis cascade
involves:
 acquisition of local invasiveness (1)
 invasion of the cell into blood/ lymph vessels (intravasation) (2)
 transport through the blood/lymph vessels to distant tissue sites (3)
 escape of the cancer cells from circulation (extravasation) (4)
 ability to adapt to the local tissue environment and to proliferate (5)

Figure 5: Steps involved in the metastatic cascade. During metastatic progression, tumour
cells exit their primary sites of growth (local invasion, intravasation; 1 & 2), translocate
systemically (survival in the circulation, arrest at a distant organ site, extravasation; 3 & 4),
and adapt to survive and thrive in foreign microenvironments (5). Adapted from Valastyan S
and Weinberg RA, Cell 147, 275-292, 2011.

Epithelial-mesenchymal transition (EMT) is a key transition enabling cancer cells
to become motile and invasive, and ultimately form metastases in distant tissues.
Cell motility is regulated by small G proteins that are activated by cytoplasmic
signalling pathways controlling the assembly of new actin cytoskeleton. Cell
invasiveness is enhanced through overexpression of various matrix
metalloproteinases (MMPs) that degrade components of the ECM.
Angiogenesis, the growth of the new blood vessels, is necessary for solid tumours
to continue growing beyond a certain size. More than a dozen different proteins and
several small molecules are released by tumours as signals for angiogenesis. Two
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proteins most important for sustaining tumour growth are vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF).
4. Stromal microenvironment and carcinogenesis
Cross talk between stromal cells within the ECM and tumour cells is also vital for
carcinogenesis. The following factors are thought to contribute to malignant
transformation:
 Cleavage of matrix components releases angiogenic factors (VEGF) promoting
new vessel growth and proteolytic fragments that favour cancer cell motility.
 The ECM stores GFs in inactive forms, which are released by active matrix
proteases and stimulate the growth of tumour cells in a paracrine manner.
 Stromal cells within the ECM may directly transmit oncogenic signals to tumour
cells.

VI. Other Genetic Aspects of Cancers
Apart from the three major types of genes frequently altered in cancer, i.e. tumour
suppressor genes, proto-oncogenes and DNA repair genes, there are several other
genetic alterations observed in tumours, which will be briefly described here.
1. Genetic instability of tumour cells
Genetic analysis of solid tumours revealed the presence of a high degree of genetic
abnormalities, such as aneuploidy, chromosome translocations etc. This is likely due
to the lack of active p53 protein, and the ability of cancer cells to avoid cell death
through apoptosis. Other mechanisms may also play a part here, e.g. mitotic defects
that result in chromosome miss-segregation. Chromosomal instability (CIN) is
widespread in cancer cells from epithelial origin, but much rarer in haematopoietic
tumours.
2. Alteration of genetic mechanisms in cancer
Three different alterations of genetic mechanisms often observed in cancer will be
briefly explained below.
Loss of heterozygosity (LOH) describes a genetic phenomenon often seen with
tumour suppressor genes in cancer. Since the human karyotype is diploid, mutation
of one allele of a tumour suppressor gene is not sufficient to cause cancer. In
heterozygous individuals, the wildtype allele will provide for a functional phenotype.
However, when a ‘second hit’ occurs, e.g. through missegregation of chromosomes,
this individual (or cell) may lose its ‘heterozygosity’, leading to a full cancerous
phenotype. Genetic analyses of LOH helped to identify the chromosomal location of
many tumour suppressor genes.
Microsatellite instability (MIN) is a phenomenon often seen in colorectal cancer
cells with defective DNA mismatch repair system, e.g. in hereditary nonpolyposis
colorectal cancer (HNPCC). Microsatellites are regions of repetitive DNA sequences
in the genome that are prone to shortening or extension if the mismatch repair
enzymes are defective. Genetic analysis of these regions can be used to identify
such defects.
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DNA hyper- or hypomethylation. DNA methylation of gene promoter regions on
CpG (cytosine-phosphate-guanine) sequences is an important epigenetic control
mechanism to silence specific genes. In cancer, DNA hypermethylation is often
involved in the silencing of tumour suppressor genes. Conversely, DNA
hypomethylation may contribute to the activation of oncogenes, although the former
occurs much more commonly.
3. Inherited predisposition to cancer
Whilst cancer as such is not inherited, there are a wide range of rare familial
syndromes that predispose affected family members to cancer development. We
mentioned above cancer predisposition syndromes that are based on mutations in
DNA repair enzyme systems (Table 4). A by far larger number of familial cancer
syndromes is based on mutations of tumour suppressor genes, of which a selection
is shown in Table 2. It is interesting to note that germ-line mutations of activated
oncogenes are normally not inherited. They may arise during gametogenesis, but the
mutant alleles are typically dominant at the cellular level, which results in disturbance
of normal embryonic development, and reduced viability of these embryos.
Fortunately, the inherited cancer predisposition syndromes listed in Tables 2 and 4
are extremely rare diseases, but they represent powerful illustrations for the
importance of DNA repair and tumour suppressor genes for maintaining body
homeostasis.
4. Principal applications of genetic testing in cancer
As an increasing number of cancer-related genes or gene mutations is characterised,
the potential of DNA and RNA expression testing for cancer-related applications is
being explored. Principal applications include:
Gene mutation screening in families with inherited cancer predisposition
syndromes, which identifies at-risk individuals in such families and allows for
decisions to be made about early disease monitoring, aggressive treatment regimens
and prophylactic surgery (e.g. mastectomy in familial breast cancer).
Gene expression microarray analysis can be used for classification of cancer
subtypes, e.g. in breast cancer or for the distinction between acute lymphoblastic and
acute myeloid leukaemia. Other applications include the diagnosis of benign vs.
malignant tumours or the monitoring of response to therapies.

VII.

Modern Treatment Modalities Arising from Cancer Cell Biology
1. Tumour immunology and immunotherapy
The immune system is able to launch attacks not only against foreign invaders, but
also against body cells that may display ‘foreign’ antigens, such as cancer cells. The
‘immune surveillance theory’ is supported by the observation that the incidence of
certain cancers is drastically increased in immune-compromised patients. Tumour
cells may be recognised by the immune system through the expression of tumourassociated antigens, but the antigenicity varies considerably between different types
of antigens.
In order to avoid an attack by the immune system, tumour cells use a range of
strategies, such as suppression of expression of tumour-associated antigens or of
MHC class 1 molecules, or even counterattack against immune cells.
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Research into immunotherapy of cancers aims to devise novel strategies to
support the anti-cancer immune response; principal approaches include:
 Antigen-independent cytokine therapy (e.g. interleukins or interferons)
 Stimulating cell-mediated immune responses (adoptive T-cell transfer, vaccines)
 Passive immunotherapy using monoclonal antibodies (e.g. Herceptin, Rituxan).
2. Novel approaches arising from cancer cell biology
The progress in our knowledge about gene mutations frequently occurring in
cancers, combined with the development of modern molecular biology methods has
led to both new diagnostic tools (see section VI. 4.) and new treatment modalities
that have shown some success in the management of selected types of cancers.
The knowledge about cancer–associated genes and their role in cellular growth
signalling pathways has led to the development of a considerable number of anticancer drugs targeting such signalling pathways: 1) monoclonal antibodies that
target the extracellular domains of growth factor receptors and 2) small-molecule
inhibitors, targeting either receptor tyrosine kinases or other components of growth
signalling pathways, such as Ras, b-Raf or mTOR (Figure. 6). Two examples of
such successful anti-cancer agents are the monoclonal antibody Herceptin for the
treatment of a specific subtype of breast cancer, and the small-molecule inhibitor
Gleevec targeting the fusion protein Bcr-abl, a mutant tyrosine kinase, involved in
the development of chronic myeloic leukaemia (CML). A third group of potential
drug targets are some anti-apoptotic proteins that are frequently overexpressed in
cancer cells.

Figure 6: Targets of novel anti-cancer drugs in cellular growth signalling pathways.
The cell membrane is indicated in light grey, red diamonds represent growth factors, green
shows the growth factor receptor with the intracellular tyrosine kinase domain (Tk) indicated
by the red circle. Coloured rectangles symbolise signalling components belonging to specific
pathways (blue: PI3K/Akt pathway; ochre: Ras/MAP kinase pathway). Dotted (black) arrows
point to cell biological outcomes of these pathways. Groups of novel anticancer drugs and
their targets are shown in red.
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VIII.

Summary: The Hallmarks of Cancer
To summarise the core points, we are listing the ‘hallmarks of cancer’, which
describe the biological capabilities acquired by cells during the multistep
development of human tumours (Figure 7):

Figure 7: A summary of the six hallmarks of cancer. Additional capabilities crucial to
cancer phenotypes that are not shown here include defects in DNA repair mechanisms and
signalling interactions of the tumour microenvironment. Image sourced from Hanahan, D and
Weinberg, RA, Cell 144, 646-674, 2011.











Self-sufficiency in growth signals: Tumours have the capacity to proliferate
without external stimuli, usually as a consequence of oncogene activation.
Insensitivity to growth-inhibitory signals: Tumour cells may not respond to
molecules that are inhibitory to the proliferation of normal cells.
Evasion of apoptosis: Tumours may be resistant to programmed cell death,
as a consequence of inactivation of p53 or overexpression of anti-apoptotic
proteins.
Defects in DNA repair: Tumours may fail to repair DNA damage caused by
carcinogens or unregulated cellular proliferation.
Limitless replicative potential: Tumour cells have unrestricted proliferative
capacity, associated with maintenance of telomere length and function.
Sustained angiogenesis: Tumours are not able to grow without formation of
a vascular supply, which is induced by various factors, the most important
being vascular endothelial growth factor (VEGF).
Ability to invade and metastasise: Tumour metastases are the cause of the
vast majority of cancer deaths and depend on processes that are intrinsic to
the cell or are initiated by signals from the tissue microenvironment.
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